The oncology pharmacy in cancer care delivery in a resource-constrained setting in western Kenya

Journal of Oncology Pharmacy Practice

Volumn 18, Issue 4, 2012, Pages 406-416

  Strother, R Matthew ^a   Rao, Kamakshi V ^b   Gregory, Kelly M ^c   Jakait, Beatrice ^d   Busakhala, Naftali ^e   Schellhase, Ellen ^f   Pastakia, Sonak ^f   Krzyzanowska, Monika ^g   Loehrer, Patrick J ^a  

^a INDIANA UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c Virginia Commonwealth Medical Center   (United States)

^d MOI TEACHING AND REFERRAL HOSPITAL   (Kenya)

^e MOI UNIVERSITY   (Kenya)

^f PURDUE UNIVERSITY   (United States)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

Africa; cancer; capacity development; developing world; Kenya; oncology pharmacy; resource constrained

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER THERAPY; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HEALTH CARE PLANNING; HEALTH HAZARD; HEALTH SERVICE; HUMAN; KENYA; NEOPLASM; ONCOLOGY PHARMACY; PHARMACY; PRIORITY JOURNAL; RISK REDUCTION; WORKPLACE;

ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; HEALTH RESOURCES; HUMANS; KENYA; NEOPLASMS; PHARMACIES;

EID: 84867043627     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155211434852     Document Type: Article

References (43)

1. Garcia M, Jemal A, Ward E, Center M, Hao Y, Siegel R, et al Global Cancer Facts & Figure 2007. Atlanta, GA: American Cancer Society ; 2007 :
2. Kanavos P. The rising burden of cancer in the developing world. Ann Oncol. 2006 ; 17 (suppl-8). viii15 - viii23
3. Lingwood RJ, Boyle P, Milburn A, Ngoma T, Arbuthnott J, McCaffrey R, et al. The challenge of cancer control in Africa. Nat Rev Cancer. 2008 ; 8 (5). 398-403
4. Kerr D, Midgley R. Can we treat cancer for a dollar a day? Guidelines for low-income countries. N Engl J Med. 2010 ; 363: 801-803
5. Scaling up cancer diagnosis and treatment in developing countries: what can we learn from the HIV/AIDS epidemic?. Ann Oncol. 2010 ; 21 (4). 680-682
6. Schrag D. The price tag on progress-chemotherapy for colorectal cancer. N Engl J Med. 2004 ; 351 (4). 317-319
7. Hesseling PB, Molyneux E, Tchintseme F, Welbeck J, McCormick P, Pritchard-Jones K, et al. Treating Burkitt's lymphoma in Malawi, Cameroon, and Ghana. Lancet Oncol. 2008 ; 9 (6). 512-513
8. Dedicoat M, Newton R. Treatment of Kaposi's sarcoma in resource-poor settings. Trop Doct. 2005 ; 35 (1). 60-60
9. Hesseling P, Broadhead R, Mansvelt E, Louw M, Wessels G, Borgstein E, et al. The 2000 Burkitt lymphoma trial in Malawi. Pediatr Blood Cancer. 2005 ; 44 (3). 245-250
10. Howard SC, Pedrosa M, Lins M, Pedrosa A, Pui C-H, Ribeiro RC, et al. Establishment of a pediatric oncology program and outcomes of childhood acute lymphoblastic leukemia in a resource-poor area. JAMA. 2004 ; 291 (20). 2471-2475
11. Omar S. The Fakous experience: meeting the challenge of cancer in a low resource setting. Breast J. 2007 ; 13 (3). 318-319
12. Anderson M, Brassington D, Bolger J. Development and operation of a pharmacy-based intravenous cytotoxic reconstitution service. Br Med J (Clin Res Ed). 1983 ; 286 (6358). 32-36
13. Knowles RS, Virden JE. Handling of injectable antineoplastic agents. Br Med J. 1980 ; 281 (6240). 589-591
14. Selevan SG, Lindbohm ML, Hornung RW, Hemminki K. A study of occupational exposure to antineoplastic drugs and fetal loss in nurses. N Engl J Med. 1985 ; 313 (19). 1173-1178
15. Valanis B, Vollmer WM, Labuhn K, Glass A, Corelle C. Antineoplastic drug handling protection after OSHA guidelines. Comparison by profession, handling activity, and work site. J Occup Med. 1992 ; 34 (2). 149-155
16. Valanis BG, Vollmer WM, Labuhn KT, Glass AG. Association of antineoplastic drug handling with acute adverse effects in pharmacy personnel. Am J Hosp Pharm. 1993 ; 50 (3). 455-462
17. Valanis B, Vollmer W, Labuhn K, Glass A. Occupational exposure to antineoplastic agents and self-reported infertility among nurses and pharmacists. J Occup Environ Med. 1997 ; 39 (6). 574-580
18. Valanis B, Vollmer WM, Steele P. Occupational exposure to antineoplastic agents: self-reported miscarriages and stillbirths among nurses and pharmacists. J Occup Environ Med. 1999 ; 41 (8). 632-638
19. Yodaiken RE, Bennett D. OSHA work-practice guidelines for personnel dealing with cytotoxic (antineoplastic) drugs. Occupational Safety and Health Administration. Am J Hosp Pharm. 1986 ; 43 (5). 1193-1204
20. Safe handling of cytotoxics. J Oncol Pharm Pract. 2007 ; 13 (Suppl). 1-81
21. Wools-Kaloustian K, Kimaiyo S, Diero L, Siika A, Sidle J, Yiannoutsos CT, et al. Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. Aids. 2006 ; 20 (1). 41-48
22. Einterz RM, Kimaiyo S, Mengech HNK, Khwa-Otsyula BO, Esamai F, Quigley F, et al. Responding to the HIV pandemic: the power of an academic medical partnership. Acad Med. 2007 ; 82 (8). 812-818
23. Einterz RM, Kelley CR, Mamlin JJ, Van Reken DE. Partnerships in international health. The Indiana University-Moi University experience. Infect Dis Clin North Am. 1995 ; 9 (2). 453-455
24. WHO. Counterfeit medicines, available at http://www.who.int/medicines/ services/counterfeit/impact/ImpactF-S/en/index1.html (accessed 12 July 2011)
25. Mahnik SN, Rizovski B, Fuerhacker M, Mader RM. Development of an analytical method for the determination of anthracyclines in hospital effluents. Chemosphere. 2006 ; 65 (8). 1419-1425
26. Mbongwe B, Mmereki BT, Magashula A. Healthcare waste management: current practices in selected healthcare facilities, Botswana. Waste Manag. 2008 ; 28 (1). 226-233
27. Fasola G, Aita M, Marini L, Follador A, Tosolini M, Mattioni L, et al. Drug waste minimisation and cost-containment in Medical Oncology: two-year results of a feasibility study. BMC Health Serv Res. 2008 ; 8 (1). 70-70
28. Field K, Zelenko A, Kosmider S, Court K, Ng L-L, Hibbert M, et al. Dose rounding of chemotherapy in colorectal cancer: an analysis of clinician attitudes and the potential impact on treatment costs. Asia-Pacific J Clin Oncol. 2010 ; 6 (3). 203-209
29. Felici A, Verweij J, Sparreboom A. Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer. 2002 ; 38 (13). 1677-1684
30. Mathijssen RHJ, de Jong FA, Loos WJ, van der Bol JM, Verweij J, Sparreboom A. Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?. Oncologist. 2007 ; 12 (8). 913-923
31. Mwanda WO, Orem J, Fu P, Banura C, Kakembo J, Onyango CA, et al. Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East Africa. J Clin Oncol. 2009 ; 27 (21). 3480-3488
32. Sterling L, van Lonkhuijzen L, Nyangena J, Orango E, Strother M, Busakhala N, et al. Protocol development for ovarian cancer treatment in Kenya: a brief report. Int J Gynecol Cancer. 2011 ; 21 (2). 424-427
33. Dranitsaris G, Truter I, Lubbe MS, Sriramanakoppa NN, Mendonca VM, Mahagaonkar SB. Improving patient access to cancer drugs in India: using economic modeling to estimate a more affordable drug cost based on measures of societal value. Int J Technol Assess Health Care. 2011 ; 27 (01). 23-30
34. Vanni T, Fonseca BA, Polanczyk CA. Cost-effectiveness analysis comparing chemotherapy regimens in the treatment of AIDS-related Kaposi's sarcoma in Brazil. HIV Clin Trials. 2006 ; 7 (4). 194-202
35. Kanavos P. The rising burden of cancer in the developing world. Ann Oncol. 2006 ; 17 (Supplement 8). viii15 - viii23
36. Farmer P, Frenk J, Knaul FM, Shulman LN, Alleyne G, Armstrong L, et al. Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet. 2010 ; 376 (9747). 1186-1193
37. Carrington C, Stone L, Koczwara B, Searle C, Siderov J, Stevenson B, et al. The Clinical Oncological Society of Australia (COSA) guidelines for the safe prescribing, dispensing and administration of cancer chemotherapy. Asia-Pacific J Clin Oncol. 2010 ; 6 (3). 220-237
38. Connor TH, McDiarmid MA. Preventing occupational exposures to antineoplastic drugs in health care settings. CA Cancer J Clin. 2006 ; 56 (6). 354-365
39. Green E, Johnston M, Trudeau M, Schwartz L, Poirier S, Macartney G, et al. Safe handling of parenteral cytotoxics: recommendations for Ontario. J Oncol Pract. 2009 ; 5 (5). 245-249
40. Livneh J, Waddington K, Bar J. Addressing safety issues of health care personnel, family members, and the environment. J Clin Oncol. 2010 ; 28 (13). e209 - e209
41. Turci R, Minoia C. Residual hazard assessment related to handling of antineoplastic drugs: safety system evolution and quality assurance of analytical measurement. Ann New York Acad Sci. 2006 ; 1076 (1). 649-656
42. Ishikawa K, Katz M, Hill-Besinque K. Graduate programs in advanced pharmacy practice in oncology in Japan. Am J Pharm Educ. 2010 ; 74 ( 6 ):
43. Yoshida J, Kosaka H, Nishida S, Kumagai S. Actual conditions of the mixing of antineoplastic drugs for injection in hospitals in Osaka Prefecture, Japan. J Occup Health. 2008 ; 50 (1). 86-91